49,291 Shares in LivaNova PLC $LIVN Bought by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in LivaNova PLC (NASDAQ:LIVN) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 49,291 shares of the company’s stock, valued at approximately $4,053,000.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Maverick Capital Ltd. bought a new stake in shares of LivaNova in the 1st quarter valued at about $956,000. Renaissance Technologies LLC boosted its stake in LivaNova by 15.7% during the 1st quarter. Renaissance Technologies LLC now owns 183,000 shares of the company’s stock worth $11,631,000 after acquiring an additional 24,900 shares during the last quarter. Quantinno Capital Management LP boosted its stake in LivaNova by 263.8% during the 1st quarter. Quantinno Capital Management LP now owns 55,562 shares of the company’s stock worth $3,532,000 after acquiring an additional 40,289 shares during the last quarter. Hsbc Holdings PLC grew its holdings in LivaNova by 260.6% during the fourth quarter. Hsbc Holdings PLC now owns 20,301 shares of the company’s stock valued at $1,255,000 after purchasing an additional 14,671 shares during the period. Finally, Rhenman & Partners Asset Management AB grew its holdings in LivaNova by 258.5% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 190,000 shares of the company’s stock valued at $11,691,000 after purchasing an additional 137,000 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Stock Performance

Shares of LivaNova stock opened at $78.93 on Thursday. The firm has a market cap of $4.35 billion, a price-to-earnings ratio of 23.35 and a beta of 0.87. The stock’s 50-day moving average is $80.56 and its 200-day moving average is $73.22. LivaNova PLC has a one year low of $48.82 and a one year high of $85.76. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.45 and a quick ratio of 1.21.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.17. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The business had revenue of $390.59 million during the quarter, compared to the consensus estimate of $380.50 million. During the same period last year, the company earned $1.05 earnings per share. LivaNova’s quarterly revenue was up 10.8% on a year-over-year basis. Equities analysts predict that LivaNova PLC will post 3.77 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Francesco Bianchi sold 1,650 shares of LivaNova stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $79.72, for a total value of $131,538.00. Following the sale, the director directly owned 7,934 shares in the company, valued at $632,498.48. This trade represents a 17.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Brooke Story sold 2,300 shares of the business’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $81.42, for a total transaction of $187,266.00. Following the completion of the sale, the director directly owned 7,488 shares in the company, valued at approximately $609,672.96. This represents a 23.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on LIVN. Piper Sandler reiterated an “overweight” rating and issued a $90.00 target price (up from $87.00) on shares of LivaNova in a report on Wednesday, September 2nd. Freedom Capital raised shares of LivaNova to a “hold” rating in a report on Tuesday, June 30th. Weiss Ratings raised shares of LivaNova from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, August 18th. Zacks Research cut shares of LivaNova from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Finally, Needham & Company LLC raised their price objective on LivaNova from $81.00 to $93.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Six research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $84.12.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.